FDA cites Novo for 850 infractions spanning 2 years

The FDA posted a scathing warning letter sent in December to Novo Nordisk about a plant in Novo Alle, Bagsvaerd, Denmark. The FDA says that over two years the plant failed to collect nearly 850 samples for environmental testing. The Swedish insulin specialist could not be reached for comment, but in issuing its earnings report recently it acknowledged the letter and said, "Novo Nordisk does not expect the letter to have an impact on products currently marketed in the U.S."